Mostly, elevated levels of sPD-L1 in plasma correlated with decreased CR rates and poorer survivals in DLBCL patients even with high-dose chemotherapy [58,59,60], despite the negative result of data by Keane et al. [61]. Here, SPDL1 is linked to diffuse large B-cell lymphoma.